ContextLogic Inc. (LOGC)
NASDAQ: LOGC · Real-Time Price · USD
7.10
+0.14 (2.01%)
Nov 22, 2024, 4:00 PM EST - Market closed
ContextLogic Revenue
ContextLogic had revenue of $96.00M in the twelve months ending September 30, 2024, down -73.11% year-over-year. In the year 2023, ContextLogic had annual revenue of $287.00M, down -49.74%.
Revenue (ttm)
$96.00M
Revenue Growth
-73.11%
P/S Ratio
1.86
Revenue / Employee
$212,389
Employees
452
Market Cap
186.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Qurate Retail | 10.24B |
Stoneridge | 919.56M |
Medifast | 674.48M |
Lanvin Group | 409.96M |
Full House Resorts | 279.13M |
Smart Share Global | 269.75M |
Clarus | 269.41M |
Envela | 165.95M |
LOGC News
- 16 days ago - ContextLogic Inc. Reports Third-Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - ContextLogic Inc. Reports Second-Quarter Financial Results - GlobeNewsWire
- 2 years ago - Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics - Business Wire
- 2 years ago - LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates - PRNewsWire
- 2 years ago - LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC - Business Wire
- 2 years ago - LogicBio's stock skyrockets after buyout bid for a 667% premium - Market Watch
- 2 years ago - AstraZeneca pays 660% premium for gene therapy firm LogicBio - Reuters
- 2 years ago - Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine - Business Wire